Shin Nippon Biomedical Laboratories (FRA:YB3) Beta: 0.5154 (As of Jun. 27, 2026)


FRA:YB3 Shin Nippon Biomedical Laboratories Ltd FRA:YB3
74 GF Score
Price €6.00
GF Value €9.47
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Beta?

Shin Nippon Biomedical Laboratories FRA:YB3 +1.69% 74 Beta is 0.5154 as of Jun. 27, 2026. GuruFocus rates FRA:YB3 with a GF Score™ of 74/100 and a GF Value™ of €9.47. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Shin Nippon Biomedical Laboratories's Beta is 0.5154.


Shin Nippon Biomedical Laboratories  (FRA:YB3) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Shin Nippon Biomedical Laboratories Beta Related Terms


Shin Nippon Biomedical Laboratories Beta Historical Data

* Premium members only.

The historical data trend for Shin Nippon Biomedical Laboratories's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shin Nippon Biomedical Laboratories Beta Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 -0.18 -0.15 -0.39 0.71

Shin Nippon Biomedical Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.07 0.50 0.62 0.71

FRA:YB3 vs TMO, DHR, IDXX: Beta Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Beta distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Beta falls into.


FRA:YB3
74GF Score
Shin Nippon Biomedical Laboratories Ltd FRA:YB3
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shin Nippon Biomedical Laboratories Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5154 mean?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a Beta of 0.5154 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Shin Nippon Biomedical Laboratories and its competitors.
Is Shin Nippon Biomedical Laboratories' Beta too high?
Shin Nippon Biomedical Laboratories' current Beta is 0.5154. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Beta compare to TMO and DHR?
Shin Nippon Biomedical Laboratories' Beta of 0.5154 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Beta is 0.5154. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a current Beta of 0.5154. The stock's GF Value™ is €9.47, compared to a current price of €6.00 — trading 36.6% below its estimated fair value. The current Beta is 0.5154. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (FRA:YB3), the current Beta is 0.5154 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (FRA:YB3) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of €6.00 is trading 36.6% below its estimated GF Value™ of €9.47.

Key valuation signals for FRA:YB3:

  • Beta: 0.5154
  • GF Value™: €9.47 vs. price of €6.00 (36.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:YB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for FRA:YB3

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€9.47
GF Value